Neuronetics Launches New Website to Meet Patient Demand for Depression Resources
August 17 2021 - 8:31AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced its new website to meet
consumer demand for information on accessing advanced treatments
for depression. The enhanced site also makes it easier for
healthcare providers to learn more about this important treatment
option for their patients. NeuroStar Advanced Therapy for Mental
Health is the leading non-drug and non-invasive transcranial
magnetic stimulation (TMS) treatment for depression.
In a recent market research survey commissioned by Neuronetics,
67 percent of patients with Major Depressive Disorder (MDD) said
they were unhappy with their current treatment; 60 percent wish
there were better options; and 56 percent were extremely interested
in learning about new treatment options for depression –
underscoring the critical need for more mental health resources and
awareness on available non-drug alternatives. Aligning with this
research, the Company’s updated website now has added content in a
centralized hub to reflect what patients need to make informed
decisions about treating depression.
“We are a company that cares about getting people well and
transforming lives,” said Keith J. Sullivan, President and CEO of
Neuronetics. “As we face a mental health pandemic on the heels of
the COVID-19 pandemic, it is more important than ever to arm
patients and providers with the resources they need to overcome
depression – especially since we know many patients are unhappy
with their current treatments and open to new options like
NeuroStar. Enhancing the user experience and revamping our website
to highlight reliable, need-to-know information about NeuroStar as
an available treatment is one of the many ways we are making it
easier for people to tackle depression.”
In addition to a seamless, improved user experience and easier
navigation, the redesigned website further advances key
conversations around depression and includes:
- Depression-related content for individuals to
determine whether NeuroStar Advanced Therapy for Mental Health
could be a treatment to consider
- Updated physician locator tool to help
prospective patients find a NeuroStar provider by distance, free
consultation availability or Stellar Distinctions designation based
on the number of patients treated
- New NeuroStar patient and provider success
stories highlighting the in-office experience and
depression relief possible for patients treated with NeuroStar
As the TMS market leader, Neuronetics understands the patient
journey and continues to innovate its educational materials to help
those with depression who haven’t had success with antidepressant
medications. The patient insights research coupled with rising
depression rates – with four in ten adults in the US reporting
symptoms of depression or anxiety connected to the COVID-19
pandemic1 – validates Neuronetics’ important commitment to
transform lives and address an unmet need for patients.
The website is designed to encourage open dialogue around mental
health and connect patients, caregivers and others with doctors
directly. The site will be updated with new resources as they
become available. To learn more, visit www.neurostar.com.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, NeuroStar® Advanced Therapy for Mental Health, is a
non-invasive and non-systemic office-based treatment that uses
transcranial magnetic stimulation, or TMS, to create a pulsed,
MRI-strength magnetic field that induces electrical currents
designed to stimulate specific areas of the brain associated with
mood. The system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. Visit NeuroStar.com for safety information and indications
for use. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national
health insurance. Additional information can be found
at www.neuronetics.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
1
https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/,
accessed 7/6/21
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2023 to Apr 2024